Cymbalta for Fibromyalgia Pain - Predictive Value of Small Fiber Changed
NCT ID: NCT01619566
Last Updated: 2019-08-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
2012-06-30
2015-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Assess Mechanisms in Peripheral Tissue Innervation for Fibromyalgia
NCT01127490
A Study of Duloxetine in Fibromyalgia
NCT01552057
An Extension Study of Duloxetine in Fibromyalgia (Extension of F1J-JE-HMGZ, NCT01552057)
NCT01621191
Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome
NCT00190866
A Study for Adult Patients With Fibromyalgia
NCT00965081
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Control subjects undergo a skin biopsy.
No interventions assigned to this group
Treatment
Subjects in the treatment arm also undergo a skin biopsy, followed by 8 week treatment with Duloxetine.
Duloxetine
oral tablet, 30mg daily for 1 week (titration up) oral tablet, 60mg daily for 8 weeks (treatment) oral tablet, 30mg daily for 1 week (titration down, if needed)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Duloxetine
oral tablet, 30mg daily for 1 week (titration up) oral tablet, 60mg daily for 8 weeks (treatment) oral tablet, 30mg daily for 1 week (titration down, if needed)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Female
* Over the age of 18, under the age of 70
* Understands English
* Not Pregnant/planning to become pregnant
* Female
* Over the age of 18, under the age of 70
* Understands English
* Not Pregnant/planning to become pregnant
Exclusion Criteria
* No major unconrolled systemic diseases which may require hospitalization in the next 6 months
* Pregnant
* No major psychiatric disorders
* No major unconrolled systemic diseases which may require hospitalization in the next 6 months
* Pregnant
18 Years
70 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, San Diego
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tobias Moeller-Bertram
Associate Clinical Professor of Anesthesia
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
tobias moeller-bertram, MD
Role: PRINCIPAL_INVESTIGATOR
employee
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, San Diego Medical Centers
San Diego, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Drug manufacturers website for study drug
Website for location of study
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
111654
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.